Psychiatrists′ perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 36, Issue 4, 2014, Pages 486-493

  Best Shaw, Lauren ^a   Gudbrandsen, Maria ^a   Nagar, Jessica ^b   Rose, Diana ^a   David, Anthony S ^a   Patel, Maxine X ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MHRN North London Hub   (United Kingdom)

Author keywords

Antipsychotics; Attitude; Dose; Plasma concentration; Schizophrenia; Therapeutic drug monitoring

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE PALMITATE; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PATIENT ATTITUDE; PATIENT PREFERENCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; QUESTIONNAIRE; SCHIZOPHRENIA; UNITED KINGDOM; CROSS-SECTIONAL STUDY; ENGLAND; MIDDLE AGED; PROCEDURES; PSYCHIATRY; PSYCHOTIC DISORDERS;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; HUMANS; LONDON; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PSYCHIATRY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SURVEYS AND QUESTIONNAIRES;

EID: 84904552670     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000041     Document Type: Article

References (40)

1. Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192:435-439.
2. Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67:160-161.
3. Tsutsumi C, Uchida H, Suzuki T, et al. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr Res. 2011;130:40-46.
4. National Institute of Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2009. NICE clinical guideline 82. Available at: http://www.nice.org.uk/nicemedia/live/11786/43608/43608.pdf. Accessed February 28, 2013.
5. Barnes TRE; Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25: 567-620.
6. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 11th ed. West Sussex, UK: Wiley-Blackwell; 2012.
7. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
8. Stahl SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol. 2004;7:113-116.
9. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder- a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392-400.
10. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686-693.
11. Sparshatt A, Taylor D, Patel MX, et al. Amisulpride-dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand. 2009;120:416-428.
12. Bishara D, Olofinjana O, Sparshatt A, et al. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy and response. J Clin Psychopharmacol. 2013;33:329-335.
13. Patel MX, Haddad PM, Chaudhry IB, et al. Psychiatrists' use, knowledge and attitudes to first and second generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24: 1473-1482.
14. Correll CU, Shaikh L, Gallego JA, et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131:58-62.
15. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46:359-388.
16. McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Australas Psychiatry. 2008;16:263-267.
17. Couchman L, Morgan PE, Spencer EP, et al. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993- 2007. Ther Drug Monit. 2010;32:438-447.
18. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
19. Bowskill SV, Handley SA, Fisher DS, et al. Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010. Ther Drug Monit. 2012;34:349-355.
20. Bowskill SV, Patel MX, Handley SA, et al. Plasma amisulpride in relation to prescribed dose, clozapine augmentation and other factors: data from a therapeutic drug monitoring service, 2002-2010. Hum Psychopharmacol. 2012;27:507-513.
21. Patel MX, Bowskill S, Couchman L, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. J Clin Psychopharmacol. 2011;31:411-417.
22. Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole- dose, plasma concentration, receptor occupancy and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71:1447-1456.
23. Sparshatt A, Taylor D, Patel MX, et al. Quetiapine-dose, plasma concentration, receptor occupancy and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2011;72:1108-1123.
24. Handley SA, Bowskill SV, Patel MX, et al. Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2010. Ther Adv Psychopharmacol. 2013;3: 129-137.
25. BMJ Group. British National Formulary (BNF). London, UK: Royal Pharmaceutical Society of Great Britain; 2012.
26. Patel MX, Arista IA, Taylor M, et al. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res. 2013; 149:141-148.
27. Hamann J, Mendel R, Cohen R, et al. Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. Psychiatr Serv. 2009;60:1107-1112.
28. Faries DE, Ascher-Svanum H, Nyhuis AW, et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9:54.
29. Linden M, Pyrkosch L, Dittmann RW, et al. Why do physicians switch from one antipsychotic agent to another? The "Physician Drug Stereotype". J Clin Psychopharmacol. 2006;26:225-231.
30. Nielsen J, Dahm M, Lublin H, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24: 965-971.
31. Seto K, Dumontet J, Ensom MH. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit. 2011;33: 275-283.
32. McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/ sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010;10:45.
33. Remington G, Agid O, Foussias G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl). 2013;225:505-518.
34. Conca A, Schmidt E, Pastore M, et al. Therapeutic drug monitoring in Italian psychiatry. Pharmacopsychiatry. 2011;44:259-262.
35. Miles SW, Wheeler A, Davies K. Determining what practising clinicians believe about long-acting injectable antipsychotic medication. Int J Psychiatry Clin Pract. 2011;15:135-144.
36. Haen E. Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry. 2011;44:254-258.
37. Sernyak MJ, Dausey D, Desai R, et al. Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv. 2003;54:246-248.
38. Mann K, Hiemke C, Schmidt LG, et al. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit. 2006;28:83-88.
39. Castberg I, Spigset O. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric highsecurity unit. Ther Drug Monit. 2008;30:597-603.
40. Couchman L, Bowskill SV, Handley S, et al. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged ,<18 years: data from a therapeutic drug monitoring service, 1994- 2010. Early Interv Psychiatry. 2013;7:122-130.